2017
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting
Kaufman H, Atkins M, Dicker A, Jim H, Garrison L, Herbst R, McGivney W, Silverstein S, Wigginton J, Yu P. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. Journal For ImmunoTherapy Of Cancer 2017, 5: 38. PMCID: PMC5394621, DOI: 10.1186/s40425-017-0241-6.Peer-Reviewed Original ResearchImmunotherapy of cancerCancer immunotherapyThird-party payersBroad clinical activityDurable response rateImmune-based agentsCurrent therapeutic strategiesVariety of malignanciesDistinct side effectsPatient advocacy groupsTraditional cytotoxicsTreatment of cancerConventional therapyPredictive biomarkersClinical activityImmunotherapyClinical OncologyTherapeutic strategiesHealthcare costsSide effectsResponse rateCancerTherapyNational HarborAmerican Society
2002
Monoclonal antibodies to target epidermal growth factor receptor–positive tumors
Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors. Cancer 2002, 94: 1593-1611. PMID: 11920518, DOI: 10.1002/cncr.10372.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorAnti-EGFR monoclonal antibodiesMonoclonal antibodiesHuman tumorsEnglish-language literature searchEpidermal growth factor receptor (EGFR) positive tumorsMonoclonal antibody therapyReceptor-positive tumorsEGFR monoclonal antibodyDevelopment of malignancyGrowth of tumorsABX-EGFGrowth factor receptorIMC-C225Overall survivalAntibody therapyTraditional cytotoxicsCommon malignancyPoor prognosisClinical trialsEpithelial tumorsVivo effectsTumor managementUnmet needEMD 55900